Navigation Links
Cryo-Cell International's Stem Cell Research and Development Helps the Fight Against Breast Cancer
Date:10/6/2009

OLDSMAR, Fla., Oct. 6 /PRNewswire-FirstCall/ -- Cryo-Cell International, a global leader in stem cell innovation, is proud to be making progress in the fight against breast cancer through research and development using stem cells from menstrual blood. In honor of National Breast Cancer Awareness Month, Cryo-Cell is supporting Susan G. Komen for the Cure® through C'elle®, the company's service which enables women to collect and cryopreserve stem cells from their menstrual blood.

Cryo-Cell is currently in a research partnership with the National Institutes of Health (NIH) Clinical Center, where research is underway to better understand the C'elle stem cells and their potential benefit for the treatment of breast cancer. Stem cells from menstrual blood are proven to be a rich source of stem cells which proliferate rapidly and have the ability to become many different types of cells. Since launching its proprietary service nearly two years ago, the company continues to expand research and development initiatives in order to accelerate the potential diagnostic and therapeutic benefits of these unique stem cells.

According to the American Cancer Society, there are 2.5 million breast cancer patients and survivors today, and an estimated one in eight women will be stricken with this disease at some point in her life. As a part of Cryo-Cell's commitment to finding treatments for breast cancer and to celebrate the promise of C'elle stem cells, the company is donating $25 to Susan G. Komen for the Cure for every enrollment in the C'elle service, and $50 for every enrollment in its Protect Baby Protect Mom(SM) package throughout the month of October.

"We at Cryo-Cell continue to dedicate significant resources toward the fight against breast cancer, and emerging science is very promising," said Cryo-Cell CEO Mercedes Walton. "Through our partnership with the National Institutes of Health, it is exciting to have such an i
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
3. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
4. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
5. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
6. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
7. Cryo-Cell Renews Upromise Industry-Exclusive Agreement
8. Cryo-Cell International, Inc. Reports First Quarter 2009 Results
9. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
10. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... N.J., Aug. 14 DOR BioPharma, Inc. (OTC Bulletin Board: DORB) ... financial results for the second quarter of 2009. , ... National Institutes of Health (NIH) grants, for the second quarter of ... second quarter of 2008. Revenues for the first half of ...
... , ... Virtual Skin™ Technology from CellWorks Group Demonstrates Possibilities for ISP,s Vincience™ Biofunctional Ingredients, ... ... therapy design company, and ISP Personal Care, a global supplier of advanced personal ...
... , , WORCESTER, Mass., Aug. 13 ... Lanza, its Chief Scientific Officer, is featured on Deepak Chopra,s Wellness Radio ... pm - 1 pm ET; Replays 1 pm - 4 am (Sunday) ... research at ACTC and his new book "Biocentrism." SIRIUS XM Stars ...
Cached Biology Technology:DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 5Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 2Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 3Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 4Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 3
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... and smooth sailing for oceanic vessels has been impeded ... pollution and greenhouse gas emissions that impact the Earth,s ... and James Corbett examines "Emission Tradeoffs among Alternative Marine ... Gas Oil, and Marine Diesel Oil," in a recent ...
... WASHINGTON, Sept. 8 The 2009 Force Protection ... County Regional Airport,Stafford, VA, and Marine Corps Base, ... is: Impacting the Global War on Terror., ... kind featuring live,presentations of commercial off-the-shelf equipment solutions ...
... paper by a team of researchers led by Shahriar ... University of Notre Dame, provides important new insights into ... The cell wall is a critically important entity ... a rigid entity encasing the bacterium, and antibiotics are ...
Cached Biology News:Fuel emissions from marine vessels remain a global concern 22009 Force Protection Equipment Demonstration Set for Next May 19-21 2
... 5 ml of DETACHaBEAD 19 polyclonal ... CD19 (Pan B). B cells ... and released with DETACHaBEAD CD19 are ... suitable for applications such as culturing ...
This Malachite Green Phosphate Detection Kit...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
...
Biology Products: